Intuniv vs Kapvay

MEDICATION COMPARISON · FROM FDA LABELS AND HEAD-TO-HEAD STUDIES

Reviewed by Tariq Halim, MD · Last medical review: October 29, 2026 · Editorial policy

Intuniv and Kapvay are both FDA-approved ADHD medicines. Intuniv contains guanfacine and Kapvay contains clonidine. No head-to-head trial compares them, so this page compares label facts only and does not rank them. Facts below come from each product’s FDA label.

Side-by-side facts (from each FDA label)

Each cell is copied from that product’s key facts, which cite its current FDA prescribing information. Durations and doses come from each product’s own label studies; they are not a head-to-head comparison.

IntunivKapvay
Drug classAlpha-2A Adrenergic Agonist · NonstimulantsAlpha-2 Adrenergic Agonist · Nonstimulants
Active ingredientguanfacineclonidine
Studied ages (label)6–17 years (monotherapy or adjunct to a stimulant)6–17 years (monotherapy or adjunct to a stimulant)
Form and strengthsExtended-release tablet; 1 mg, 2 mg, 3 mg, 4 mg extended-release tabletsExtended-release tablet; 0.1 mg extended-release tablet (generic)
Usual dose and maximum (label)Start 1 mg once daily, increasing by no more than 1 mg per week; target 0.05–0.12 mg/kg/day (1–7 mg/day).Start 0.1 mg at bedtime; maximum 0.4 mg/day, split into morning and bedtime doses.
Duration (label)Taken once daily, every day; the label does not describe hour-by-hour effects (half-life about 18 hours).Taken twice daily, every day; the label does not describe hour-by-hour effects (half-life about 12–13 hours).
DEA scheduleNot a controlled substanceNot a controlled substance
GenericAB-rated generics (see Generic manufacturers)AB1 generics (see Generic manufacturers)
Label datePrescribing Information revised 06/2025 (DailyMed)Prescribing Information revised 10/2025 (DailyMed)
Availability (site status, Oct 2026)See trackerBrand discontinued

Main differences in plain words

  • Intuniv contains guanfacine; Kapvay contains clonidine.
  • Form: Intuniv: extended-release tablet; Kapvay: extended-release tablet.
  • Controlled status: both: Not a controlled substance.
  • Generic: Intuniv: AB-rated generics; Kapvay: AB1 generics.

What studies compare them

No direct comparison. No head-to-head trial of Intuniv and Kapvay is in this site’s verified evidence base, so this page does not say that one works better than the other. The studies below give context only.

  • Meta-analysis

    Alpha-2 agonists (clonidine IR/ER, guanfacine ER), youth

    A meta-analysis of 12 trials (2,276 youth) found clonidine and guanfacine reduced ADHD symptoms more than placebo, alone or added to a stimulant (smaller effect when added). Tiredness, sedation and sleepiness were more common, and clonidine lowered blood pressure and heart rate.

    Pools guanfacine and clonidine trials against placebo; it does not compare the two medicines with each other.

    SR/MA (to May 2013): 12 RCTs, N=2,276. Monotherapy (9 studies, n=1,550): overall ADHD SMD −0.59, hyperactivity/impulsivity −0.56, inattention −0.57, ODD −0.44. Add-on (3 studies, n=726): SMD −0.36. Monotherapy all-cause discontinuation RR 0.70 (NNT 10); fatigue NNH 10, sedation NNH 17, somnolence NNH 4; hypotensive and bradycardic effects with clonidine-IR, QTc prolongation with guanfacine-XR; add-on: hypotension/bradycardia with clonidine-XR and guanfacine-XR.

    Hirota T, Schwartz S, Correll CU (2014). Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 53(2):153-73. DOI · PubMed 24472251

  • Network meta-analysis

    ADHD treatments in children and teens (class)

    Across 190 trials in children and teens, methylphenidate, amphetamine, atomoxetine, guanfacine and clonidine all worked better than placebo. Methylphenidate and amphetamine appeared more effective than atomoxetine and guanfacine. Behavioral therapy combined with a stimulant appeared better than either medicine type alone. Most effective medicines also caused harms such as reduced appetite, weight loss and sleep problems.

    Reports guanfacine and clonidine each against placebo; this site’s summary of the abstract has no guanfacine-versus-clonidine result.

    Bayesian network meta-analyses of 190 RCTs (52 interventions, 26,114 participants; ≥3 weeks follow-up). Medications more efficacious than placebo: methylphenidate, amphetamine, atomoxetine, guanfacine, clonidine. Methylphenidate and amphetamine more efficacious than atomoxetine and guanfacine; methylphenidate and clonidine better accepted (all-cause discontinuation) than placebo and atomoxetine. Behavioural therapy plus stimulants appeared superior to stimulants or nonstimulants alone. Harms included anorexia, weight loss and insomnia. Results expressed as ORs with credible intervals (not reproduced here).

    Catalá-López F, Hutton B, Núñez-Beltrán A, et al. (2017). The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One 12(7):e0180355. DOI · PubMed 28700715

Switching between them (label)

What each FDA label says about starting it after another medicine. Switch the clinician view on to see the full label wording and any dose tables. More in the switching guide.

Intuniv (label section 2.3, Prescribing Information, revised 06/2025): From short-acting guanfacine, the dose is worked out again.

From immediate-release guanfacine: stop and titrate; do not substitute milligram-for-milligram (differing pharmacokinetics).

Kapvay (label section 2.1, Prescribing Information, revised 10/2025): Other clonidine products are not swapped at the same dose.

Substituting clonidine ER tablets for other clonidine products mg-per-mg is not recommended (no controlled trial data; differing pharmacokinetics).

For clinicians

Label facts are from each product’s current prescribing information (Intuniv: revised 06/2025; Kapvay: revised 10/2025). Evidence summaries show the study detail and funding; comparative statements are limited to head-to-head trials, analyses of them and network meta-analyses. Indirect comparisons (for example, matching-adjusted indirect comparisons) are not used for efficacy claims.

Talk to your prescriber. These two medicines are not interchangeable at the same dose unless a label says so. Bring this page to your appointment if it helps, but do not change, stop or swap medicines on your own.

Frequently asked questions

What is the difference between Intuniv and Kapvay?

Intuniv contains guanfacine (extended-release tablet); Kapvay contains clonidine (extended-release tablet). Intuniv: Not a controlled substance. Kapvay: Not a controlled substance. The side-by-side table on this page lists approved ages, doses, duration and generic status from each label.

Is Intuniv more effective than Kapvay?

No head-to-head trial of Intuniv and Kapvay is in this site’s verified evidence base, so there is no direct evidence that one works better. Both are FDA-approved for ADHD in the ages shown on their labels.

Which lasts longer, Intuniv or Kapvay?

Per the labels: Intuniv: Taken once daily, every day; the label does not describe hour-by-hour effects (half-life about 18 hours). Kapvay: Taken twice daily, every day; the label does not describe hour-by-hour effects (half-life about 12–13 hours). These figures come from separate label studies, not from one study comparing the two.

Can you switch from Intuniv to Kapvay?

Neither label gives a milligram conversion between these two products. Intuniv label: From immediate-release guanfacine: stop and titrate; do not substitute milligram-for-milligram (differing pharmacokinetics). Kapvay label: Substituting clonidine ER tablets for other clonidine products mg-per-mg is not recommended (no controlled trial data; differing pharmacokinetics). Any switch is planned and adjusted by the prescriber.

Are Intuniv and Kapvay available as generics?

Intuniv: AB-rated generics. Kapvay: AB1 generics. Current supply is tracked on the availability tracker page.

Sources

  • Takeda Pharmaceuticals America, Inc. Intuniv (guanfacine) extended-release tablets. Prescribing Information, revised 06/2025. DailyMed (accessed Oct 2026).
  • Ajanta Pharma USA Inc. Clonidine hydrochloride extended-release tablets. Prescribing Information, revised 10/2025. DailyMed (accessed Oct 2026).
  • Hirota T, Schwartz S, Correll CU Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014;53(2):153-73. PubMed
  • Catalá-López F, Hutton B, Núñez-Beltrán A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One. 2017;12(7):e0180355. PubMed
EDUCATIONAL INFORMATION ONLY. Not medical advice. Medication decisions require individualized assessment by a qualified clinician. Do not start, stop, switch or change the dose of a medication without your prescriber. See the medical disclaimer.
Back to top